FIELD: medicine.
SUBSTANCE: group of inventions relates to monoclonal antibodies to alpha-synuclein and their use for inhibiting tau-protein aggregation, when treating tauopathy. Proposed antibodies to alpha-synuclein are capable of neutralizing alpha-synuclein aggregates or preventing incoming of alpha-synuclein aggregates to neurons or glial cells and preventing facilitation of tau-protein aggregation.
EFFECT: antibodies can be used for the treatment of tauopathies, such as Alzheimer’s disease and others, wherein a patient to be treated does not have an Alzheimer’s disease option with Lewy bodies or a combined Parkinson-Alzheimer disease.
7 cl, 9 dwg, 7 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODIES THAT RECOGNIZE ALPHA-SYNUCLEINE | 2012 |
|
RU2743738C2 |
| ANTIBODIES AGAINST ALPHA SYNUCLEIN | 2018 |
|
RU2787039C2 |
| ANTIBODIES THAT BIND TO α-SYNUCLEIN PROTOFIBRILS | 2021 |
|
RU2810587C1 |
| ANTIBODIES | 2018 |
|
RU2798399C2 |
| AGENTS, APPLICATION WAYS AND METHODS FOR TREATING SYNUCLEOPATHY | 2016 |
|
RU2765303C2 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND OPTIONS OF THEIR USE | 2019 |
|
RU2812765C2 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
